ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML	B-cell acute lymphoblastic leukemia, B-cell neoplasm, Burkitt lymphoma, Chronic Disease, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, bone marrow disorder, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, myeloid leukemia, neoplasm, viral infectious disease	Recruiting	Phase 1	2025-11-04		NCT03595917

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Marlise Luskin, MD	1
Novartis	114

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Beth Israel Deaconess Medical Center	Boston	United States	462
Dana Farber Cancer Institute	Boston	United States	133
Roswell Park Comprehensive Cancer Center	Buffalo	United States	32
University of Chicago Comprehensive Cancer Center	Chicago	United States	273